Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (463)	9/22/2006 4:26:26 PM
From: Biomaven	Read Replies (1) \| Respond to of 510

I'm assuming that by the time you see a mass in a scan it's too late for this test - you are going to biopsy the tumor no matter what the test says. The role of the test surely has to be earlier, in deciding whether to do a scan or not to begin with. These sensitivity/specificity numbers aren't good enough so that you could use this in general screening. The question remains whether they could identify a subgroup of the general population where the test would be useful - has to be some group where there is a moderate index of suspicion - if there is a high index you are going to proceed to a scan anyhow and then biopsy if there is continued suspicion after the scan. Peter